56 related articles for article (PubMed ID: 11917284)
1. The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801.
Lawrence YR; Paulus R; Langer C; Werner-Wasik M; Buyyounouski MK; Komaki R; Machtay M; Smith C; Axelrod RS; Wasserman T; Bradley JD; Movsas B
Lung Cancer; 2013 Jun; 80(3):298-305. PubMed ID: 23477890
[TBL] [Abstract][Full Text] [Related]
2. Effects of selenomethionine on acute toxicities from concurrent chemoradiation for inoperable stage III non-small cell lung cancer.
Mix M; Ramnath N; Gomez J; de Groot C; Rajan S; Dibaj S; Tan W; Rustum Y; Jameson MB; Singh AK
World J Clin Oncol; 2015 Oct; 6(5):156-65. PubMed ID: 26468452
[TBL] [Abstract][Full Text] [Related]
3. Endostar acts as a pneumonitis protectant in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiotherapy.
Chen K; Li S; Chen M; Jin Z; Sun X; Zhou S; Yang H
BMC Cancer; 2024 Feb; 24(1):257. PubMed ID: 38395838
[TBL] [Abstract][Full Text] [Related]
4. A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer.
Zheng Q; Min S; Zhou Y
BMC Cancer; 2022 Jun; 22(1):674. PubMed ID: 35725420
[TBL] [Abstract][Full Text] [Related]
5. Radiation-Induced Lung Injury-Current Perspectives and Management.
Rahi MS; Parekh J; Pednekar P; Parmar G; Abraham S; Nasir S; Subramaniyam R; Jeyashanmugaraja GP; Gunasekaran K
Clin Pract; 2021 Jul; 11(3):410-429. PubMed ID: 34287252
[TBL] [Abstract][Full Text] [Related]
6. Amifostine- and chemoradiotherapy-related esophagitis in small cell lung cancer: a single institutional series and literature update.
Pollock AE; Shinn L; Anderson R; Butler S; Pollock J
Lung Cancer (Auckl); 2018; 9():79-84. PubMed ID: 30237747
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of amifostine in elderly cancer patients.
Barutca S; Meydan N; Akar H; Yavasoglu I; Kadikoylu G; Bolaman Z
Curr Ther Res Clin Exp; 2004 Jan; 65(1):113-24. PubMed ID: 24936110
[TBL] [Abstract][Full Text] [Related]
8. Systematic review of agents for the management of gastrointestinal mucositis in cancer patients.
Gibson RJ; Keefe DM; Lalla RV; Bateman E; Blijlevens N; Fijlstra M; King EE; Stringer AM; van der Velden WJ; Yazbeck R; Elad S; Bowen JM;
Support Care Cancer; 2013 Jan; 21(1):313-26. PubMed ID: 23142924
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology of iron transport.
Byrne SL; Krishnamurthy D; Wessling-Resnick M
Annu Rev Pharmacol Toxicol; 2013; 53():17-36. PubMed ID: 23020294
[TBL] [Abstract][Full Text] [Related]
10. Prediction of radiation pneumonitis in lung cancer patients: a systematic review.
Zhang XJ; Sun JG; Sun J; Ming H; Wang XX; Wu L; Chen ZT
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2103-16. PubMed ID: 22842662
[TBL] [Abstract][Full Text] [Related]
11. Current trends in the management of oral mucositis related to cancer treatment.
Biswal BM
Malays J Med Sci; 2008 Jul; 15(3):4-13. PubMed ID: 22570584
[TBL] [Abstract][Full Text] [Related]
12. Zebrafish as a model system to screen radiation modifiers.
Hwang M; Yong C; Moretti L; Lu B
Curr Genomics; 2007 Sep; 8(6):360-9. PubMed ID: 19412436
[TBL] [Abstract][Full Text] [Related]
13. Choice of radiotherapy planning modality influences toxicity in the treatment of locally advanced esophageal cancer.
Mackley HB; Adelstein JS; Reddy CA; Adelstein DJ; Rice TW; Saxton JP; Videtic GM
J Gastrointest Cancer; 2008; 39(1-4):130-7. PubMed ID: 19407936
[TBL] [Abstract][Full Text] [Related]
14. Oral mucositis induced by anticancer treatments: physiopathology and treatments.
Lionel D; Christophe L; Marc A; Jean-Luc C
Ther Clin Risk Manag; 2006 Jun; 2(2):159-68. PubMed ID: 18360589
[TBL] [Abstract][Full Text] [Related]
15. Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors.
Tsuboi M; Le Chevalier T
Med Oncol; 2006; 23(2):161-70. PubMed ID: 16720916
[TBL] [Abstract][Full Text] [Related]
16. Amifostine in the management of radiation-induced and chemo-induced mucositis.
Bensadoun RJ; Schubert MM; Lalla RV; Keefe D
Support Care Cancer; 2006 Jun; 14(6):566-72. PubMed ID: 16586122
[TBL] [Abstract][Full Text] [Related]
17. Understanding the mechanisms of drug-associated interstitial lung disease.
Higenbottam T; Kuwano K; Nemery B; Fujita Y
Br J Cancer; 2004 Aug; 91 Suppl 2(Suppl 2):S31-7. PubMed ID: 15340376
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results.
Komaki R; Lee JS; Kaplan B; Allen P; Kelly JF; Liao Z; Stevens CW; Fossella FV; Zinner R; Papadimitrakopoulou V; Khuri F; Glisson B; Pisters K; Kurie J; Herbst R; Milas L; Ro J; Thames HD; Hong WK; Cox JD
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):46-9. PubMed ID: 11917284
[TBL] [Abstract][Full Text] [Related]
19. Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer.
Antonadou D
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):50-8. PubMed ID: 11917285
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
